Alberton F, Nozza S, Raccagni AR, Galli L, et al. The Propensity for Long-Acting Cabotegravir and Rilpivirine Every Two Months Among HIV-Infected People Eligible for Treatment. J Med Virol 2022 Nov 22. doi: 10.1002/jmv.28330.
PMID: 36415058